Hansen’s Disease (Leprosy) – A Complete Medical Guide
Overview
Hansen’s disease, more commonly known as leprosy, is a chronic infectious disease caused by the bacterium Mycobacterium leprae. The organism primarily attacks the skin, peripheral nerves, the mucosa of the upper respiratory tract, and the eyes. If left untreated, it can lead to permanent nerve damage, disability, and social stigma.
Leprosy is a disease of the poor and marginalized, but anyone can become infected—regardless of age, gender, or ethnicity. The World Health Organization (WHO) reports that in 2022, about 127,000 new cases were detected worldwide, a sharp decline from the >5 million cases reported in the 1990s thanks to effective multidrug therapy (MDT). The disease remains endemic in 23 countries, with Brazil, India, and Indonesia accounting for ~80% of global cases.1
Symptoms
Leprosy has a long incubation period (typically 2–7 years, but can be up to 20 years), so symptoms may appear slowly. The clinical picture depends on the host’s immune response and is classified on a spectrum from tuberculoid (paucibacillary) to lepromatous (multibacillary).
Skin lesions
- Hypopigmented or reddish patches—lighter than surrounding skin, often with decreased sensation.
- Raised plaques or nodules—especially in lepromatous disease; may be thickened and shiny.
- Hair loss (alopecia) over the lesion.
- Temperature changes—lesions may feel cooler or warmer than normal skin.
Nerve involvement
- Loss of sensation—numbness or tingling in the hands, feet, or face.
- Peripheral neuropathy—muscle weakness, especially in the hands and feet, leading to claw hand or foot drop.
- Enlarged peripheral nerves—palpable thickening of the ulnar, median, radial, or peroneal nerves.
Eye problems
- Dryness and irritation (due to reduced blinking).
- Corneal ulceration—can lead to vision loss if untreated.
Other systemic signs
- Nasal congestion or chronic rhinitis.
- Enlarged lymph nodes in lepromatous disease.
- Fever, weight loss, and malaise—more common in multibacillary disease.
Because early lesions can resemble common skin conditions (e.g., eczema or fungal infection), a high index of suspicion is essential, especially in endemic areas or in individuals with known exposure.
Causes and Risk Factors
Etiology
The disease is caused by Mycobacterium leprae, an acid‑fast bacillus that grows slowly and cannot be cultivated on standard laboratory media. Transmission occurs primarily via prolonged close contact with an untreated individual, most likely through respiratory droplets (nasal secretions). The bacterium also persists in the environment—armadillos in the southern United States are a known zoonotic reservoir.2
Risk factors
- Living in or traveling to endemic regions (South‑East Asia, parts of Africa, South America).
- Close, repeated exposure to an untreated patient, especially household members.
- Genetic susceptibility—certain HLA types increase risk.
- Immunosuppression—e.g., HIV infection, chronic steroid use.
- Poor socioeconomic conditions—overcrowding, limited access to health care.
- Occupational exposure—working with armadillos or in animal labs.
Diagnosis
Diagnosing leprosy relies on clinical assessment supported by laboratory tests. Early diagnosis is crucial to prevent disability.
Clinical evaluation
- Detailed skin examination for characteristic lesions.
- Neurological assessment—testing sensation with a monofilament, checking for nerve enlargement.
- Slit‑skin smear (SSS) from multiple sites to detect acid‑fast bacilli.
Laboratory tests
- Skin smear microscopy—Ziehl‑Neelsen staining; a positive result confirms multibacillary disease.
- Skin biopsy—histopathology shows granulomas (tuberculoid) or foamy macrophages (lepromatous). Special stains (Fite‑faraco) highlight the bacilli.
- Polymerase chain reaction (PCR)—detects bacterial DNA; useful when smear is negative.
- Serologic tests (e.g., anti‑PGL‑1 antibodies)—help in monitoring lepromatous cases but are not diagnostic alone.
Classification for treatment
The WHO classifies patients for therapy based on the number of skin lesions and smear results:
- Paucibacillary (PB) – ≤5 skin lesions, negative smear.
- Multibacillary (MB) – >5 lesions or positive smear.
Treatment Options
Since 1981, leprosy has been curable with multidrug therapy (MDT). The regimen differs according to classification.
Standard WHO MDT regimens
| Form | PB (≤6 months) | MB (12 months) |
|---|---|---|
| Rifampicin (R) | 600 mg once monthly supervised | 600 mg once monthly supervised |
| Dapsone (D) | 100 mg daily self‑administered | 100 mg daily self‑administered |
| Clofazimine (C) | 50 mg daily + 300 mg once monthly supervised | 50 mg daily + 300 mg once monthly supervised |
All medicines are provided free of charge by the WHO global leprosy programme.3
Adjunctive treatments
- Prednisone for acute neuritis to reduce inflammation and prevent permanent nerve loss (usually 1 mg/kg taper over weeks).
- Physiotherapy and occupational therapy to maintain muscle strength and joint mobility.
- Eye care—lubricating drops, protective glasses, and regular ophthalmology review.
- Reconstruction surgery for severe deformities (e.g., tendon release, claw hand correction).
Lifestyle and supportive measures
- Nutrition: Adequate protein, vitamins (especially B12, D) to support nerve health.
- Skin care: Daily moisturizing, gentle cleaning, and protection of anesthetic areas from injury.
- Psychosocial support: Counseling, support groups, and anti‑stigma education.
Living with Hansen’s Disease (Leprosy)
Most patients complete MDT without major complications and can lead normal lives. The key is ongoing self‑care and regular follow‑up.
Daily management tips
- Protect numb areas—use soft footwear, avoid sharp objects, and inspect feet daily for cuts or burns.
- Maintain skin hygiene—bathe gently, keep lesions clean, and apply prescribed ointments.
- Eye protection—use lubricating drops 3–4 times daily, wear sunglasses, and avoid drying environments.
- Adhere to medication—take dapsone and clofazimine exactly as prescribed; set reminders if needed.
- Exercise—light stretching and strengthening to preserve joint range of motion.
- Nutrition—eat a balanced diet rich in fruits, vegetables, and lean protein.
- Regular medical visits—monthly during MDT, then every 6–12 months for surveillance.
- Address stigma—join community groups, educate family and coworkers, and seek legal protection if discrimination occurs.
Reintegration and work
Successful treatment restores the ability to work. Employers are legally required (e.g., under the UN Convention on the Rights of Persons with Disabilities) to provide reasonable accommodations. Vocational rehabilitation programs are available in many endemic countries.
Prevention
Although a vaccine for leprosy does not exist, several public‑health measures dramatically lower transmission.
- Early case detection and prompt MDT reduce the infectious period.
- Contact tracing—examine household members; give single‑dose rifampicin prophylaxis to eligible contacts (WHO recommendation).
- Education—inform communities that leprosy is curable and not highly contagious.
- Improved living conditions—adequate housing, reduced crowding, and better nutrition.
- Personal protective measures—for healthcare workers, use masks when dealing with untreated patients with nasal discharge.
Complications
If treatment is delayed or incomplete, leprosy can cause irreversible damage.
Physical complications
- Neuropathy & loss of sensation – leading to repeated injuries, secondary infections, and ulceration.
- Deformities – e.g., claw hand, foot drop, facial palsy, and nasal collapse (saddle‑nose).
- Eye complications – corneal ulcers, cataracts, or blindness.
- Secondary bacterial infections – especially in ulcerated lesions.
Psychosocial complications
- Stigma and discrimination, which can cause depression, anxiety, and social isolation.
- Economic hardship from loss of employment.
Rare but serious
- Leprosy reactions (type 1 reversal reaction or type 2 erythema nodosum leprosum) – acute inflammation that may worsen nerve damage.
- Coinfection with HIV or tuberculosis – can alter disease course and complicate treatment.
When to Seek Emergency Care
Call emergency services (or go to the nearest emergency department) if you experience any of the following:
- Sudden loss of sensation in an extremity accompanied by severe pain or swelling (possible acute neuritis).
- Rapidly spreading redness, warmth, or foul‑smelling discharge from a skin lesion (sign of secondary infection).
- Severe eye pain, vision loss, or a white spot on the cornea (possible corneal ulcer).
- High fever (>38.5 °C / 101.3 °F) with chills, confusion, or difficulty breathing.
- Signs of a severe leprosy reaction such as painful nodules, fever, or worsening nerve pain.
Prompt medical attention can prevent permanent nerve damage and other serious outcomes.
References
- World Health Organization. Leprosy (Hansen’s disease) Fact Sheet. 2023. https://www.who.int/news-room/fact-sheets/detail/leprosy
- Centers for Disease Control and Prevention. Leprosy – Transmission. 2022. https://www.cdc.gov/leprosy/transmission.html
- Mayo Clinic. Leprosy (Hansen disease). 2024. https://www.mayoclinic.org/diseases-conditions/leprosy/symptoms-causes/syc-20353543
- Cleveland Clinic. Leprosy (Hansen’s Disease). 2023. https://my.clevelandclinic.org/health/diseases/16254-leprosy-hansens-disease
- NIH National Institute of Allergy and Infectious Diseases. Leprosy Treatment. 2022. https://www.niaid.nih.gov/diseases-conditions/leprosy